US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

What To Know About State-Level PBM Reform No Photo Available

Yeji Jesse Lee

Healthcare attorneys are keeping a close eye on new laws focused on the vertical integration of pharmacy benefit managers.

No Slowdown: A Midyear Look At FDA Ad Enforcement No Photo Available

Dan McKay

An FDA drug ad enforcement surge that began last year continued in the first half of 2026. Experts say the agency is looking hard at t... (more story)

What To Know About The Missouri Abortion Law Ruling No Photo Available

Mark Payne

Nearly two years after Missouri residents enshrined reproductive rights into the state constitution, a judge ruled that more than thre... (more story)